SGLT2 inhibitors are also useful against osteosarcoma, as evidenced by Wu et al. In their study, they found that canagliflozin significantly inhibited osteosarcoma tumor growth with a concomitant infiltration of immune cells in vivo [45]. Here, SLC5A2 is linked to neoplasm.